Phaseline

Targets › MET

MET (Hepatocyte growth factor receptor): drug programs, companies and trials

43 programs from 35 companies in 241 trials: 122 Phase 2, 84 Phase 1, 31 Phase 3, 4 Phase 4; Oncology, Gastroenterology, Immunology; next expected readout Nov 2026.

Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. (UniProt, P08581)

Open in Phaseline: the race on MET, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ExelixisCabozantinib (XL184)
Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor
KDR, METPhase 4Medullary Thyroid Cancer; Hepatocellular Carcinoma; Metastatic Prostate Cancer; Renal Cell Carcinoma …Jan 2027
Pfizercrizotinib
Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
MET, ALK, EML4, NPM1, ROS1Phase 4NSCLCMar 2028
AstraZenecasavolitinib
Hepatocyte growth factor receptor inhibitor
METPhase 3Carcinoma; Papillary Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Lung Cancer …Nov 2026
ExelixisZanzalintinib (XL092)
Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL
FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRAPhase 3Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma …Dec 2026
National Cancer Institute (NCI)Cabozantinib S-malate
Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor
KDR, METPhase 3Functioning Pancreatic Neuroendocrine Tumor; Clear Cell Renal Cell Carcinoma; Advanced Bladder Urothelial Carcinoma; Differentiated Thyroid Gland Carcinoma …Dec 2026
Johnson & Johnson (Janssen)Amivantamab
Epidermal growth factor receptor erbB1 inhibitor; Hepatocyte growth factor receptor inhibitor
EGFR, METPhase 3Advanced or Metastatic Non-small Cell Lung Cancer; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck …Dec 2026
Beijing Pearl Biotechnology Limited Liability CompanyPLB1001 (Vebreltinib)
MET inhibitor
METPhase 3Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; GlioblastomaDec 2026
Chia Tai Tianqing Pharmaceutical GroupAL2846 Capsule
Multi-target tyrosine kinase inhibitor targeting c-MET, c-KIT, VEGFR1, and RET
MET, KIT, FLT4, RETPhase 3Thyroid CancerJan 2027
IDEAYA BiosciencesCrizotinib
Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor
MET, ALK, EML4, NPM1, ROS1Phase 3Uveal Melanoma; Metastatic Uveal Melanoma; ALK Gene Rearrangement; Advanced Lymphoma …Jan 2027
AbbVieTelisotuzumab adizutecan
Anti-MET antibody-drug conjugate
METPhase 3Colorectal Cancer; Metastatic Colorectal Cancer; Pancreatobiliary Cancers; Head and Neck Squamous Cell Carcinoma …Jul 2027
AbbVieTelisotuzumab Vedotin (ABBV-399)
Tubulin inhibitor; Hepatocyte growth factor receptor binding agent
Tubulin, METPhase 3Non Small Cell Lung Cancer; Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; Advanced Solid Tumors Cancer …Feb 2028
ApollomicsAPL-101
MET inhibitor
METPhase 2Solid Tumors; Metastatic Non Small Cell Lung CancerNov 2026
Hansoh BioMedical R&D CompanyHS-20117-2 Injection
EGFR-MET bispecific antibody
EGFR, METPhase 2Non-Squamous Non-Small Cell Lung Cancer; Solid Tumors; Advanced Solid TumorsDec 2026
Eli LillyMerestinib (LY2801653)
Hepatocyte growth factor receptor inhibitor
METPhase 2Biliary Tract CancerDec 2026
Sichuan Kelun-Biotech BiopharmaceuticalSKB571
MET inhibitor
METPhase 2Non-small Lung Cancer; Gastrointestinal Tumors; Lung Cancer (Non-Small Cell); HNSCC …Dec 2026
Beijing Scitech-Mq PharmaceuticalsST-1898
Receptor tyrosine kinase (RTK) inhibitor targeting VEGFR2, c-MET, AXL, PDGFRA, RET, and KI
VEGFR2, MET, AXL, PDGFRA, RETPhase 2Differentiated Thyroid Carcinoma; Unresectable or Metastatic Melanoma; Advanced Renal Cell CarcinomaDec 2026
Avistone BiotechnologyVebreltinib
MET inhibitor
METPhase 2Non-Small-Cell Lung Cancer; Clear Cell Sarcoma (CCS)Dec 2026
M.D. Anderson Cancer CenterCabozantinib S-malate
Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor
KDR, METPhase 2Malignant Neoplasms of Urinary Tract; Locally Advanced Osteosarcoma; Brain Metastases; Advanced Breast Carcinoma …Apr 2027
NovartisCapmatinib
Hepatocyte growth factor receptor inhibitor
METPhase 2Advanced Solid Tumors Which Are cMET-dependent; EGFR-mutant Non-small Cell Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; Solid TumourJul 2027
Shanghai EpimAb BiotherapeuticsBafisontamab (EMB-01)
Hepatocyte growth factor receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor
MET, EGFRPhase 2Metastatic Colorectal Cancer; Unresectable/Metastatic Colorectal CancerDec 2027
AbionABN401 (vabametkib)
c-MET inhibitor
METPhase 2Advanced Solid TumorsFeb 2029
Yonsei UniversityABN401
c-MET inhibitor
METPhase 2Neoplasms–
Merck KGaATepotinib
Hepatocyte growth factor receptor inhibitor
METPhase 2Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification; Advanced Non Small Cell Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; Non-Small Cell Lung Cancer Metastatic …–
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalTQB2922 for injection
anti-EGFR/c-Met bispecific antibody
EGFR, METPhase 1Advanced Cancer; RAS/BRAF Wild Type Colorectal CancerDec 2026
AstraZenecaFPI-2053
Bispecific antibody targeting EGFR and cMET
EGFR, METPhase 1Advanced Solid TumorDec 2026
AstraZeneca[111In]-FPI-2107
Imaging agent (indium-111 conjugated to FPI-2053 bispecific antibody targeting EGFR and cM
EGFR, METPhase 1Advanced Solid TumorDec 2026
AstraZeneca[225Ac]-FPI-2068
Alpha-emitting radiopharmaceutical (actinium-225) conjugated to bispecific antibody target
EGFR, METPhase 1Advanced Solid TumorDec 2026
Chia Tai Tianqing Pharmaceutical GroupTQB6411 for Injection
EGFR/c-Met dual-targeting antibody-drug conjugate
EGFR, METPhase 1Esophageal Cancer; Advanced Lung CancerFeb 2027
Turning Point Therapeuticselzovantinib (TPX-0022)
MET/CSF1R/SRC inhibitor
MET, CSF1R, SRCPhase 1Advanced Solid TumorMar 2027
Shanghai Henlius BiotechHLX48
EGFR/c-MET bispecific antibody-drug conjugate
EGFR, METPhase 1Advanced/Metastatic Solid TumorsMar 2027
Peking University Cancer Hospital & InstituteVebreltinib
c-MET inhibitor
METPhase 1Non Small Cell Lung Cancer NSCLCApr 2027
Johnson & Johnson (Janssen)Capmatinib
Hepatocyte growth factor receptor inhibitor
METPhase 1Carcinoma, Non-Small-Cell LungApr 2027
Innovent Biopharmaceutical Technology (Hangzhou)IBI3028
Recombinant anti-EGFR and c-Met antibodies dual-payload conjugate
EGFR, METPhase 1Solid TumorJun 2027
Regeneron PharmaceuticalsREGN5093 (davutamig)
MET inhibitor
METPhase 1NSCLCJul 2027
DeuterOncologyDO-2
Deuterated MET kinase inhibitor
METPhase 1Adult Solid TumorSep 2027
Full-Life Technologies UK[225Ac]Ac-FL-020
anti-c-MET targeted radioligand therapy (alpha-particle emitter conjugate)
METPhase 1Metastatic Castration-resistant Prostate Cancer; Solid TumorSep 2027
BeOne MedicinesBG-C0902
Bispecific anti-EGFR and anti-MET antibody-drug conjugate with topoisomerase 1 inhibitor p
EGFR, METPhase 1Solid TumorsNov 2027
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalTQB6411 injection
EGFR/c-Met dual-targeting antibody-drug conjugate (ADC)
EGFR, METPhase 1Advanced Malignant TumorsDec 2027
Betta PharmaceuticalsMCLA-129
bispecific antibody targeting EGFR and cMET
EGFR, METPhase 1Solid Tumor; Solid Advanced TumorApr 2028
Chong Kun Dang PharmaceuticalCKD-703
c-Met-targeting monoclonal antibody conjugated to monomethyl auristatin E (MMAE)
METPhase 1Advanced Solid TumorsDec 2029
Shanghai Chia Tai Tianqing Pharmaceutical Technology DevelopmentTQB2922 injection
Bispecific antibody against EGFR and c-Met
EGFR, METPhase 1Advanced CancersDec 2029
Pierre Fabre MedicamentVERT-002
MET inhibitor
METPhase 1Solid TumorOct 2030
MerusMCLA-129
bispecific IgG1 antibody targeting EGFR and c-MET receptor tyrosine kinases
EGFR, METPhase 1Non-Small Cell Lung Cancer Metastatic–

Conditions

Carcinoma, Non-Small-Cell Lung (12) Non-Small Cell Lung Cancer (9) Non-small Cell Lung Cancer (6) Non-Small-Cell Lung Cancer (5) Advanced Solid Tumor (5) Hepatocellular Carcinoma (5) Colorectal Cancer (5) Solid Tumor (5) Advanced Lymphoma (4) Metastatic Colorectal Cancer (4) Metastatic Renal Cell Carcinoma (4) Recurrent Lung Non-Small Cell Carcinoma (3)

Modalities

small molecule (33), mixed (8), antibody (2)

Companies

AstraZeneca (4) Johnson & Johnson (Janssen) (2) Exelixis (2) AbbVie (2) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (2) Chia Tai Tianqing Pharmaceutical Group (2) Beijing Scitech-Mq Pharmaceuticals (1) IDEAYA Biosciences (1) National Cancer Institute (NCI) (1) Shanghai Henlius Biotech (1) DeuterOncology (1) Pierre Fabre Medicament (1) Turning Point Therapeutics (1) Sichuan Kelun-Biotech Biopharmaceutical (1) Beijing Pearl Biotechnology Limited Liability Company (1) Apollomics (1) M.D. Anderson Cancer Center (1) Betta Pharmaceuticals (1) Shanghai EpimAb Biotherapeutics (1) Yonsei University (1)

Related targets

EGFR (15) KDR (3) PDGFRA (2) RET (2) ALK (2) EML4 (2) NPM1 (2) ROS1 (2) KIT (2) VEGFR2 (1) AXL (1) CSF1R (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.